(PDF) The Predictive Value of Tumor Mutation Burden for

The Predictive Value of Tumor Mutation Burden for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer Is Affected by Patients’ Age

Biomarker Research - United Kingdom

doi 10.1186/s40364-020-00188-2

Full Text

Abstract

Available in full text

Categories

Molecular Medicine

Clinical Biochemistry

Date

April 9, 2020

Authors

Publisher

Springer Science and Business Media LLC

Related search

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer Research

English

P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients With Metastatic Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.04-14 Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit From Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research

Cancer Research

English

Is Immune Checkpoint Inhibition Part of Standard Therapy for Stage III Non-Small Cell Lung Cancer?

Cancer Research

English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi

English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management

English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology

English

Safety and Tolerability of Extracranial Radiation Therapy and Immune Checkpoint Inhibitors Among Patients With Metastatic Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English